| Date | Title | Description |
| 10.04.2026 | Nine Swiss startups recognized globally |
Fast Company's annual ranking of the World's Most Innovative Companies identifies businesses setting the pace for global innovation across industries. This year's list includes two Swiss startups in category-leading positions.
Axmed (found... |
| 11.01.2026 | Enodia Therapeutics Secures €20.7M Seed Funding to Pioneer Protein Degradation with AI | Enodia Therapeutics, a pioneering biotech firm, secured a significant €20.7 million ($25 million) seed funding round. This vital capital propels its innovative small-molecule platform, a breakthrough approach targeting protein degradation a... |
| 11.01.2026 | Enodia Therapeutics Raises €20.7M to Target "Undruggable" Proteins with SEC61 Platform | Enodia Therapeutics, a Paris-based biotech, has secured €20.7 million ($25 million) in seed funding. Argobio Studio launched the company. Enodia develops small molecules. Its platform targets protein degradation at the point of synthesis. I... |
| 11.01.2026 | EpiBiologics Secures $107M Series B, Propelling Precision Protein Degradation for Cancer and Immunity | EpiBiologics closed a $107 million Series B. This investment accelerates its EpiTAC platform. The platform develops tissue-selective extracellular protein degraders. These target disease-driving membrane and soluble proteins. Lead candidate... |
| 10.01.2026 | Enodia Therapeutics: €20.7 Million Seed Funding Closed To Advance SEC61-Based Small-Molecule Protein Degradation Platform | Enodia Therapeutics has raised €20.7 million (about $25 million) in a seed financing to advance a discovery platform that uses proteomics and machine learning to develop small molecules that degrade disease-driving proteins at the point of ... |
| 10.01.2026 | EpiBiologics: $107 Million Series B Raised To Advance Tissue-Selective EGFR Degrader And Bispecific Antibody Pipeline | EpiBiologics announced it has closed a $107 million Series B financing to advance a pipeline of bispecific antibodies designed to selectively degrade extracellular protein targets in oncology and immunology. The round was co-led by GV and J... |
| 08.01.2026 | Enodia Therapeutics Raises €20.7M in Seed Funding | Enodia Therapeutics, a Paris, France-based biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, raised €20.7m (US$25m) in Seed financing.
The round was co-led by Elaia, ... |
| 08.01.2026 | EpiBiologics Closes $107M Series B Funding | EpiBiologics, a San Mateo, CA-based company which specializes in tissue-selective extracellular protein degradation, raised $107M in Series B funding.
The round was co-led by GV (Google Ventures) and Johnson & Johnson, through its corpo... |
| 18.11.2025 | Mission BioCapital closes on $143.75m for Fund VI | - |
| 29.08.2025 | Sensorium Therapeutics Raises $25M in Series A Funding | Sensorium’s current pipeline is powered by the company’s discovery platform SensAI™, which holistically integrates comprehensive biological data to identify compounds with a high probability of clinical success.
Sensorium Therapeutics, a Bo... |
| 24.12.2024 | SiteOne Therapeutics: A New Dawn in Non-Opioid Pain Management | In a world where pain management often leads to addiction, SiteOne Therapeutics is carving a new path. The San Francisco-based biotech has just secured $100 million in Series C funding, led by Novo Holdings. This investment marks a signific... |
| 18.12.2024 | Novo Holdings leads SiteOne's $100M series C for non-opioid pain treatments | SiteOne Therapeutics is powering up with $100 million to advance its early pipeline of non-opioid therapeutics that target the peripheral nervous system instead of the central nervous system.
The biotech’s series C financing was led by Novo... |
| 12.12.2024 | Alessa Therapeutics Announces Closing $15M Seed Financing | Alessa is well positioned to advance our pipeline and leverage our platform of tissue-targeted drug delivery for the treatment of prostate cancer and other solid organ diseases.”
— Pamela Munster, M.D., Founder & Chief Executive Officer... |
| 05.11.2024 | Houston's Innovation Landscape: Navigating Challenges and Embracing Opportunities | Houston is a city of dreams and determination. It’s a melting pot of innovation, where entrepreneurs are forging paths in uncharted territories. The recent Houston Innovation Awards highlighted this spirit, showcasing the wisdom of finalist... |
| 04.11.2024 | Overheard: 2024 Houston Innovation Awards finalists share top advice for fellow founders | There's a great deal of advice swirling around the world today about how to find success business. Why not take it from mentors and founders with a proven track record, like the finalists for this year's Houston Innovation Awards?
From how ... |
| 24.10.2024 | Houston's Innovation Surge: Biotech Breakthroughs and Mars Simulations | Houston is a city where innovation thrives. It’s a melting pot of ideas, where science meets ambition. Recently, two stories have emerged that highlight this vibrant ecosystem: a groundbreaking biotech company and a NASA Mars simulation mis... |
| 23.10.2024 | Clinical-stage Houston cell therapy company closes $28.4M oversubscribed series A | An emerging biotech company in Houston has closed its series A with outsized success.
March Biosciences' oversubscribed raise brought in $28.4 million of financing with Mission BioCapital and 4BIO Capital leading the pack of investors. The ... |
| 23.10.2024 | NASA taps 4 participants for Mars habitat simulation mission in Houston | Four individuals have been selected to go to Mars. Well, sort of.
Obaid Alsuwaidi, Kristen Magas, Tiffany Snyder, and Anderson Wilder were picked by NASA to live for 45 days in a 650-square-foot Mars simulation located at Johnson Space Cent... |
| 18.09.2024 | Immunos Therapeutics raises USD11 million |
ImmunOs’ lead program IOS-1002 is currently tested in a Phase Ia dose escalation clinical trial as a monotherapy and in combination with MSD’s anti-PD-1 therapy KEYTRUDA (pembrolizumab). IOS-1002 is a novel, multifunctional immunotherapy a... |
| 07.06.2022 | ImmunOs Therapeutics raises $74 Million to fund clinical trials | |
| 04.11.2021 | Google Cloud goes deep into financial services with $1 billion CME deal | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
I didn’t see this coming.
Paid Content Why empathic leadership is critical to business success Fr... |
| 17.04.2012 | Southeastern IT, life science VC firm raising $125M new fund | Like many other VC firms, Harbert says it looks for seasoned entrepreneurs building early growth stage companies in large and growing markets. Areas of focus in healthcare include medical devices, healthcare IT, healthcare services and diag... |
| - | Southeastern IT, life science VC firm raising $125M new fund | Good news for life science startups in Florida, Georgia, Virginia and other emerging hubs in the southeast U.S.: A large VC focusing its investments on information technology and healthcare is raising a new $125 million fund.
Harbert Ventur... |
